We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis released new information that showed the drug consistently reduced the risk of confirmed disability progression in secondary progressive multiple sclerosis (SPMS) patients.
Biogen’s Zinbryta multiple sclerosis drug has suffered a serious setback after European regulators restricted its use because of liver safety concerns.